Summary
In a dose of 40 mg, sotalol (MJ 1999) was more potent than 10 mg propranolol in blocking the cardiovascular effects of isoproterenol (5 healthy males, age 22–28 years). In a dose of 10 mg sotalol had weaker blocking properties. In a dose of 10 mg, propranolol under true basal conditions significantly decreased cardiac output (1.7 ± 0.34 1), stroke volume (31 ± 11 ml) and “heart work” (− 20 ± 7%), and increased the peripheral resistance (+35 ± 6%). Sotalol (10–40 mg i.v.) had no significant actions on cardiac output or any other cardiac function. There were statistically significant differences in the haemodynamic effects of sotalol and propranolol at doses producing a similar adrenergic β-receptor blocking effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Åberg, G., Dzedin, T., Lundholm, L., Olsson, L., Svedmyr, N.: A comparative study of some cardiovascular effects of sotalol (MJ 1999) and propranolol. Life Sci. 8, 353–365 (1969).
— — — — — Influence of sotalol (MJ 1999) and propranolol on some metabolic actions of adrenaline in the rabbit. Acta pharmacol. (Kbh.), in press.
Åström, H.: Haemodynamic effects of β-adrenergic blockade. Brit. Heart J. 30, 44–49 (1968).
Blinks, J.R.: Evaluation of the cardiac effects of several β-adrenergic blocking agents. Ann. N.Y. Acad. Sci. 139, 673–685 (1962).
Drabkin, D. L., Austin, J. H.: Spectrophotometric studies. V. A technique for the analysis of undiluted blood and concentrated hemoglobin solutions. J. biol. Chem. 112, 105–109 (1935).
Fisher, R. A.: Statistical methods for research workers. Edinburgh: Oliver and Boyd, 1958.
Frankl, W. S., Soloff, L. A.: Sotalol: A new safe β-adrenergic receptor blocking agent. Amer. J. Cardiol. 22, 266–272 (1968).
Hamer, J., Sowton, E.: Cardiac output after β-adrenergic blockade in ischaemic heart disease. Brit. Heart J. 27, 892 (1965).
Hoffman, R. P., Grupp, G.: The effects of sotalol and propranolol on contractile force and atrioventricular conduction time of the dog heart in situ. Dis. Chest 55, 229–234 (1969).
Holmgren, A., Pernow, B.: Spectrophotometric measurement of oxygen saturation of blood in the determination of cardiac output. A comparison with the van Slyke method. Scand. J. clip. Lab. Invest. 11, 143–149 (1959).
Lish, P. M., Shelanski, M. V. LaBudde, J. A.: Inhibition of cardiac chronotropic action of isoproterenol by sotalol (MJ 1999) in rat, dog and man. Curr. ther. Res. clin. Exp. 9, 311–323 (1967).
—, Weikel, J. H., Dungan, K. W.: Pharmacological and toxicological properties of two new β-adrenergic receptor antagonists. J. Pharmacol. exp. Therap. 149, 161–173 (1965).
Puri, P. S., Bing, R. J.: Effects on myocardial contractility, hemodynamics and cardiac metabolism of a new β-adrenergic blocking drug, sotalol. Dis. Chest 55, 235–239 (1969).
Siggaard Andersen, O., Engel, K., Jörgensen, K., Astrup, P.: A micro method for determination of pH carbon dioxide tension, base excess, and standard bicarbonate in capillary blood. Scand. J. clin. Lab. Invest. 12, 172–181 (1960).
Stanton, H. C., Kirchgessner, T., Parmenter, K. Cardiovascular pharmacology of two new β-adrenergic receptor antagonists. J. Pharmacol. exp. Ther. 149, 174–182 (1965).
Svedmyr, N., Jakobsson, B., Malmberg, R.: Effects of sotalol and propranolol administered orally in man. Europ. J. Pharmacol. 8, 79–82. (1969)
Author information
Authors and Affiliations
Additional information
This work was supported by grants from the Swedish State Medical Research Council (B69-14x-2546-01) and AB Bofors, Nobel-Pharma.
For technical assistance we are indebted to Mrs. Anna-Greta Berggren and to Mrs. Anita Andersson.
Rights and permissions
About this article
Cite this article
Svedmyr, N., Malmberg, R. & Häggendal, E. The haemodynamic effects of sotalol (MJ 1999) and propranolol in man. Pharmacol. Clin. 2, 82–85 (1970). https://doi.org/10.1007/BF00420711
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00420711